Although the introduction of treatments targeting vascular endothelial growth factor (VEGF) has decreased the incidence of legal blindness and visual impairment caused by wet AMD (Mehta et al., 2018), the underlying CNV pathophysiology and a comprehensive understanding of the biological pathways that mediate wet AMD development and progression have not yet been clarified. This evidence concerns the gene VEGFA and blindness (disorder).